Recherche
-
TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration
(Ophthalmology Science. vol. 1, n° 4, 2021-12)Article de revueLibre accès -
Faricimab Treat-and-Extend for Diabetic Macular Edema: 2-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials
(Ophthalmology: Journal of The American Academy of Ophthalmology, 2023-12-27)Article de revueLibre accès -
The impact of artificial intelligence on retinal disease management: Vision Academy retinal expert consensus
(Current Opinion in Ophthalmology. vol. 34, n° 5, pp. 396-402, 2023-09-01)Article de revueLibre accès -
Microperimetry to predict disease progression in eyes at high risk of age-related macular degeneration disease: The PREVISION study
(Acta Ophthalmologica. vol. 101, n° 2, pp. e135-e142, 2023-03)Article de revueLibre accès -
A novel tool to assess the quality of RWE to guide the management of retinal disease
(Acta Ophtalmologica, 2020-12-28)Article de revueLibre accès -
An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data
(BMC ophthalmology. vol. 18, n° 1, pp. 340, 2018-12-27)Article de revueLibre accès -
Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: post-hoc review of HAWK and HARRIER
(Ophthalmology: Journal of The American Academy of Ophthalmology, 2020-11-15)Article de revueLibre accès -
Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure
(Graefe's Archive for Clinical and Experimental Ophthalmology. vol. 259, pp. 567–574, 2021-02-02)Article de revueLibre accès -
Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases
(BMJ open ophthalmology. vol. 4, n° 1, pp. e000185, 2019)Article de revueLibre accès -
Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison
(Advances in Therapy, 2020)Article de revueLibre accès